More than half of patients who received a pancreas transplant alone experienced >50% decline in eGFR, had eGFR < 30 mL/min/1.73 m2, and/or received a kidney transplant 10 years after their initial pancreas transplant.
A trial comparing baricitinib against placebo in people with new-onset type 1 diabetes suggests use could contribute to the preservation of β-cell function.
The highest incidence of pediatric type 1 diabetes (T1D) over the past 22 years was seen in Finland, high-income North American regions, and children aged 5 to 14 years.